Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | NAMPT | P43490 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.55 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | CFD | P00746 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9613322 | 0.80 | PTPN7 (0.67) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL9613310 | 0.80 | KDM4E (0.74) | KDM4ENPC1RAB9ANAMPTALDH1A1 | |
| SCHEMBL20866569 | 0.78 | PTPN7 (0.64) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL2246316 | 0.77 | ALDH1A1 (0.87) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL9613370 | 0.76 | IKBKB (0.66) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL6979591 | 0.76 | NPC1 (0.67) | KDM4ENPC1RAB9ANAMPTALDH1A1 | |
| SCHEMBL9613315 | 0.76 | PTPN7 (0.66) | KDM4EGAALMNAL3MBTL1PTPN7 | |
| SCHEMBL6098738 | 0.75 | CFD (0.81) | KDM4EALDH1A1HPGDPOLBUSP2 | |
| SCHEMBL23921563 | 0.75 | KDM4E (0.50) | KDM4ENPC1RAB9ANAMPTALDH1A1 | |
| SCHEMBL2529343 | 0.75 | RAB9A (1.00) | KDM4ENPC1RAB9ANAMPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353094-B2 | Substituted quinoxalines as kinase inhibitors | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150274709-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | THE BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM | 2015-10-01 | — | — | US | disclosed |
| US-8993758-B2 | Substituted quinoxalines and uses thereof | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2015-03-31 | — | — | US | disclosed |
| US-20130289041-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2013-10-31 | — | — | US | disclosed |
| WO-2012071414-A2 | QUINOXALINE COMPOUNDS AND USES THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274709-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | NFKBIA, RELA, MTOR | KDM4E 1991/4885NPC1 1956/4885RAB9A 960/4885 |
| US-20130289041-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | NFKBIA, RELA, MTOR | KDM4E 1991/4885NPC1 1956/4885RAB9A 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.